Sanofi CFO says won't be affected by Novo's Catalent deal

Catalent

25/10/2024 06:30

FRANKFURT, Oct 25 (Reuters) - Sanofi's  SASY.PA  finance
chief on Friday said the company won't be affected by Novo
Nordisk's  NOVOb.CO  controlling shareholder's decision to
acquire contract drug manufacturer Catalent  CTLT.N , adding the
deal made sense for its rival. 
    "They desperately need capacity so it makes sense for them,"
Sanofi CFO Francois-Xavier Roger said in a media call after the
release of third-quarter results. 
    He added Novo paid a "very heavy price to get access to the
capacity", given very strong demand for weight-loss drugs.
    Swiss drugmaker Roche  ROG.S  on Wednesday joined peer Eli
Lilly  LLY.N  in voicing concern over the planned Catalent
takeover, saying it could hit competition in the booming
weight-loss drug industry.

 (Reporting by Ludwig Burger)
 ((ludwig.burger@thomsonreuters.com; +49 30 220133634;))